-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Il1cqQB5XMI1rnZsW5OJkeRWmrRejgiDemFhu78SDSvG/vqfECdRYLikor7W7IWA DrDS+pOn21PIpHXQ7ROBtQ== 0000903893-97-000141.txt : 19970225 0000903893-97-000141.hdr.sgml : 19970225 ACCESSION NUMBER: 0000903893-97-000141 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970204 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENEMEDICINE INC CENTRAL INDEX KEY: 0000907111 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760355802 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48153 FILM NUMBER: 97517793 BUSINESS ADDRESS: STREET 1: 8301 NEW TRAILS DRIVE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 7133641150 MAIL ADDRESS: STREET 1: 8301 NEW TRAILS DRIVE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ABINGWORTH BIOVENTURES SICAV CENTRAL INDEX KEY: 0000895906 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 231 VAL DES BONS MALADES L-2121 CITY: LUXEMBERG-KIRCHBERG STATE: N4 BUSINESS PHONE: 3524389891 MAIL ADDRESS: STREET 1: 231 VAL DES BONS MALADES STREET 2: BOITE POSTALE 566 L2015 CITY: LUXEMBOURG STATE: N4 SC 13G/A 1 SCHEDULE 13G - AMENDMENT NO.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* GeneMedicine, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 par value - -------------------------------------------------------------------------------- (Title of Class of Securities) 368707105 ------------------ (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 5 pages - -------------------------------------------------------------------------------- CUSIP NO. 368707105 13G PAGE 2 OF 5 PAGES ------ ------ - -------------------------------------------------------------------------------- - ------- ------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Abingworth Bioventures SICAV - ------- ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)[ ] (b)[ ] - ------- ------------------------------------------------------------------------ 3 SEC USE ONLY - ------- ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg - ------------------------- ----- ------------------------------------------------ 5 SOLE VOTING POWER NUMBER OF 1,192,144 shares ----- ------------------------------------------------ SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY - 0 - shares ----- ------------------------------------------------ EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 1,192,144 shares ----- ------------------------------------------------ WITH 8 SHARED DISPOSITIVE POWER - 0 - shares - ------- ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,192,144 shares - ------- ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*[ ] - ------- ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.2% - ------- ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON * CO - ------- ------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT! Page 2 of 5 Pages ITEM 1(A). Name of Issuer: GeneMedicine, Inc. ITEM 1(B). Address of Issuer's Principal Executive Offices: 8301 New Trails Drive, The Woodlands, Texas 77381 ITEM 2(A). Name of Person Filing: Abingworth Bioventures SICAV ("ABS") ITEM 2(B). Address of Principal Business Office or, if None, Residence: The address of the principal business office of ABS is 231 Val des Bons Malades, L-2121 Luxembourg-Kirchberg. ITEM 2(C). Citizenship: ABS is a corporation organized under the laws of Luxembourg. ITEM 2(D). Title of Class of Securities: Common Stock, $.001 par value. ITEM 2(E). CUSIP Number: 368707105 ITEM 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Securities Exchange Act of 1934 (the "Act"). (b) [ ] Bank as defined in Section 3(a)(6) of the Act. (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act. (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940. (e) [ ] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940. (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) of the Act. (g) [ ] Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G) of the Act. (h) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(H) of the Act. Not applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-2(b). Page 3 of 5 pages ITEM 4. Ownership. (a) Amount Beneficially Owned: ABS is the record and beneficial owner of 1,192,144 shares of Common Stock as of December 31, 1996. (b) Percent of Class: 9.2%. The foregoing percentage is calculated based on the 12,995,600 shares of Common Stock reported to be outstanding in the Quarterly Report on Form 10-Q of GeneMedicine, Inc. for the quarter ended September 30, 1996. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,192,144 shares. (ii) shared power to vote or to direct the vote: 0 shares. (iii) sole power to dispose or to direct the disposition of: 1,192,144 shares. (iv) shared power to dispose or to direct the disposition of: 0 shares. ITEM 5. Ownership of Five Percent or Less of a Class. Not applicable. ITEM 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. ITEM 8. Identification and Classification of Members of the Group. Not applicable ITEM 9. Notice of Dissolution of Group. Not applicable. ITEM 10. Certification. Not applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b). Page 4 of 5 pages SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: February 4, 1997 ABINGWORTH BIOVENTURES SICAV By: /s/ Karl U. SANNE ------------------------- Name: Karl U. SANNE Title: Director By: /s/ Fernand HEIM ------------------------- Name: Fernand HEIM Title: Mandatory Page 5 of 5 Pages -----END PRIVACY-ENHANCED MESSAGE-----